CN106943398A - 使用4‑甲基吡唑治疗人类个体的基因型特异性方法 - Google Patents
使用4‑甲基吡唑治疗人类个体的基因型特异性方法 Download PDFInfo
- Publication number
- CN106943398A CN106943398A CN201710098759.1A CN201710098759A CN106943398A CN 106943398 A CN106943398 A CN 106943398A CN 201710098759 A CN201710098759 A CN 201710098759A CN 106943398 A CN106943398 A CN 106943398A
- Authority
- CN
- China
- Prior art keywords
- individual
- adh2
- aldh2
- ethanol
- methylpyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XKVUYEYANWFIJX-UHFFFAOYSA-N 5-methyl-1h-pyrazole Chemical class CC1=CC=NN1 XKVUYEYANWFIJX-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title abstract description 77
- 230000001419 dependent effect Effects 0.000 title abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 321
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims abstract description 170
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims abstract description 54
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims abstract description 54
- 208000024891 symptom Diseases 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 238000009825 accumulation Methods 0.000 claims abstract description 33
- 230000035479 physiological effects, processes and functions Effects 0.000 claims abstract description 33
- 206010001598 Alcohol intolerance Diseases 0.000 claims abstract description 18
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 claims description 174
- 229960004285 fomepizole Drugs 0.000 claims description 174
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 claims description 153
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 claims description 149
- 230000009467 reduction Effects 0.000 claims description 64
- 230000000694 effects Effects 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 19
- 230000008030 elimination Effects 0.000 claims description 17
- 238000003379 elimination reaction Methods 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 11
- 239000003513 alkali Substances 0.000 claims description 9
- 206010019233 Headaches Diseases 0.000 claims description 8
- 206010028813 Nausea Diseases 0.000 claims description 8
- 206010047700 Vomiting Diseases 0.000 claims description 8
- 208000002173 dizziness Diseases 0.000 claims description 8
- 231100000869 headache Toxicity 0.000 claims description 8
- 230000008693 nausea Effects 0.000 claims description 8
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 208000001953 Hypotension Diseases 0.000 claims description 7
- 206010000059 abdominal discomfort Diseases 0.000 claims description 7
- 208000012866 low blood pressure Diseases 0.000 claims description 7
- 230000008673 vomiting Effects 0.000 claims description 7
- 206010003591 Ataxia Diseases 0.000 claims description 6
- 206010010947 Coordination abnormal Diseases 0.000 claims description 6
- 208000016290 incoordination Diseases 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- -1 4- methyl pyrroles Azoles Chemical class 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 claims 24
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 claims 24
- FEKWWZCCJDUWLY-UHFFFAOYSA-N 3-methyl-1h-pyrrole Chemical class CC=1C=CNC=1 FEKWWZCCJDUWLY-UHFFFAOYSA-N 0.000 claims 1
- 150000003851 azoles Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000003217 pyrazoles Chemical class 0.000 claims 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 abstract description 27
- 201000010099 disease Diseases 0.000 abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 27
- 230000002265 prevention Effects 0.000 abstract description 7
- 235000019441 ethanol Nutrition 0.000 description 116
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 25
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 18
- 108700028369 Alleles Proteins 0.000 description 16
- 239000000523 sample Substances 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 208000024558 digestive system cancer Diseases 0.000 description 6
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000013178 mathematical model Methods 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000008473 connective tissue growth Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000006866 hypopharynx cancer Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000008376 long-term health Effects 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 201000006958 oropharynx cancer Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IKHGUXGNUITLKF-MZCSYVLQSA-N 1,2,2,2-tetradeuterioethanone Chemical compound [2H]C(=O)C([2H])([2H])[2H] IKHGUXGNUITLKF-MZCSYVLQSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical class NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017856 Gastritis alcoholic Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WVVOBOZHTQJXPB-UHFFFAOYSA-N N-anilino-N-nitronitramide Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-] WVVOBOZHTQJXPB-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- WQKBEGVHVPMTRV-UHFFFAOYSA-N [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-].C(C)=O Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-].C(C)=O WQKBEGVHVPMTRV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000005988 alcoholic gastritis Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 101150095787 ldh2 gene Proteins 0.000 description 1
- 101150100271 ldhb gene Proteins 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 102200034293 rs17121818 Human genes 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18588409P | 2009-06-10 | 2009-06-10 | |
| US61/185,884 | 2009-06-10 | ||
| CN2010800352852A CN102458121A (zh) | 2009-06-10 | 2010-06-09 | 使用4-甲基吡唑治疗人类个体的基因型特异性方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800352852A Division CN102458121A (zh) | 2009-06-10 | 2010-06-09 | 使用4-甲基吡唑治疗人类个体的基因型特异性方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106943398A true CN106943398A (zh) | 2017-07-14 |
Family
ID=43309203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710098759.1A Pending CN106943398A (zh) | 2009-06-10 | 2010-06-09 | 使用4‑甲基吡唑治疗人类个体的基因型特异性方法 |
| CN2010800352852A Pending CN102458121A (zh) | 2009-06-10 | 2010-06-09 | 使用4-甲基吡唑治疗人类个体的基因型特异性方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800352852A Pending CN102458121A (zh) | 2009-06-10 | 2010-06-09 | 使用4-甲基吡唑治疗人类个体的基因型特异性方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20120252857A1 (enExample) |
| EP (2) | EP2440049B1 (enExample) |
| JP (2) | JP5836270B2 (enExample) |
| KR (3) | KR20140138318A (enExample) |
| CN (2) | CN106943398A (enExample) |
| AU (1) | AU2010258821B2 (enExample) |
| DK (1) | DK2440049T3 (enExample) |
| ES (1) | ES2656489T3 (enExample) |
| NO (1) | NO2440049T3 (enExample) |
| PT (1) | PT2440049T (enExample) |
| SG (1) | SG176734A1 (enExample) |
| TW (1) | TWI523653B (enExample) |
| WO (1) | WO2010144518A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109381458A (zh) * | 2018-12-16 | 2019-02-26 | 李志武 | 甲吡唑及其盐在制备抗癫痫药物中的用途 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901484B2 (en) * | 2012-04-27 | 2014-12-02 | Sanofi-Aventis Deutschland Gmbh | Quantification of impurities for release testing of peptide products |
| JP6421249B2 (ja) * | 2015-10-26 | 2018-11-07 | 株式会社日立製作所 | デバッグを支援する方法及び計算機システム |
| WO2019209123A1 (en) * | 2018-04-27 | 2019-10-31 | Remedius Biotech Limited | Diagnosis, risk reduction and treatment of conditions associated with elevated aldehyde levels |
| JP2025541701A (ja) * | 2022-12-01 | 2025-12-23 | ピコエンテック シーオー．，エルティーディー． | 振戦または運動障害を抑制するための新規なアルデヒドデヒドロゲナーゼを含有する食品および薬物組成物 |
| CN120475912A (zh) * | 2022-12-01 | 2025-08-12 | 匹克生物酶高科技有限公司 | 用于改善行为和运功功能的新型醛脱氢酶食品和药剂组合物 |
| WO2024117698A1 (en) * | 2022-12-01 | 2024-06-06 | PICOENTECH Co., LTD. | Food and pharmaceutical composition for detoxifying endogenous aldehydes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080021083A1 (en) * | 2004-03-03 | 2008-01-24 | Daley Thomas E | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106620A (en) | 1980-12-22 | 1982-07-02 | Takara Shuzo Co Ltd | Ameliorant for alcoholic metabolism |
| GB0404481D0 (en) | 2004-02-28 | 2004-03-31 | Rhodia Cons Spec Ltd | Soap control agent |
| WO2009058874A1 (en) * | 2007-11-02 | 2009-05-07 | Monte Woodow C | Methods and materials for treating or preventing diseases/disorders mediated by alcohol dehydrogenase |
-
2010
- 2010-06-09 KR KR1020147029368A patent/KR20140138318A/ko not_active Ceased
- 2010-06-09 WO PCT/US2010/037879 patent/WO2010144518A1/en not_active Ceased
- 2010-06-09 US US13/376,933 patent/US20120252857A1/en not_active Abandoned
- 2010-06-09 CN CN201710098759.1A patent/CN106943398A/zh active Pending
- 2010-06-09 DK DK10786733.5T patent/DK2440049T3/en active
- 2010-06-09 ES ES10786733.5T patent/ES2656489T3/es active Active
- 2010-06-09 EP EP10786733.5A patent/EP2440049B1/en not_active Not-in-force
- 2010-06-09 CN CN2010800352852A patent/CN102458121A/zh active Pending
- 2010-06-09 EP EP17206781.1A patent/EP3311811A1/en not_active Withdrawn
- 2010-06-09 TW TW099118855A patent/TWI523653B/zh not_active IP Right Cessation
- 2010-06-09 PT PT107867335T patent/PT2440049T/pt unknown
- 2010-06-09 SG SG2011090883A patent/SG176734A1/en unknown
- 2010-06-09 AU AU2010258821A patent/AU2010258821B2/en not_active Ceased
- 2010-06-09 JP JP2012515088A patent/JP5836270B2/ja not_active Expired - Fee Related
- 2010-06-09 NO NO10786733A patent/NO2440049T3/no unknown
- 2010-06-09 KR KR1020167023761A patent/KR20160147709A/ko not_active Ceased
- 2010-06-09 KR KR1020127000590A patent/KR20120032523A/ko not_active Ceased
-
2012
- 2012-06-21 US US13/529,695 patent/US20120322843A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015060341A patent/JP2015155422A/ja active Pending
-
2016
- 2016-09-20 US US15/270,842 patent/US20170007578A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/788,504 patent/US20180098964A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080021083A1 (en) * | 2004-03-03 | 2008-01-24 | Daley Thomas E | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109381458A (zh) * | 2018-12-16 | 2019-02-26 | 李志武 | 甲吡唑及其盐在制备抗癫痫药物中的用途 |
| CN109381458B (zh) * | 2018-12-16 | 2020-09-01 | 李志武 | 甲吡唑及其盐在制备抗癫痫药物中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5836270B2 (ja) | 2015-12-24 |
| US20180098964A1 (en) | 2018-04-12 |
| KR20160147709A (ko) | 2016-12-23 |
| DK2440049T3 (en) | 2018-02-19 |
| EP3311811A1 (en) | 2018-04-25 |
| JP2015155422A (ja) | 2015-08-27 |
| TWI523653B (zh) | 2016-03-01 |
| AU2010258821B2 (en) | 2016-03-10 |
| US20120322843A1 (en) | 2012-12-20 |
| ES2656489T3 (es) | 2018-02-27 |
| SG176734A1 (en) | 2012-01-30 |
| JP2012529526A (ja) | 2012-11-22 |
| CN102458121A (zh) | 2012-05-16 |
| KR20140138318A (ko) | 2014-12-03 |
| WO2010144518A1 (en) | 2010-12-16 |
| US20120252857A1 (en) | 2012-10-04 |
| NO2440049T3 (enExample) | 2018-05-12 |
| TW201110966A (en) | 2011-04-01 |
| EP2440049B1 (en) | 2017-12-13 |
| EP2440049A1 (en) | 2012-04-18 |
| PT2440049T (pt) | 2018-03-05 |
| US20170007578A1 (en) | 2017-01-12 |
| KR20120032523A (ko) | 2012-04-05 |
| EP2440049A4 (en) | 2012-12-05 |
| AU2010258821A1 (en) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106943398A (zh) | 使用4‑甲基吡唑治疗人类个体的基因型特异性方法 | |
| Šagud et al. | Smoking in schizophrenia: an updated review | |
| Ostadal et al. | Gender differences in cardiac ischemic injury and protection—experimental aspects | |
| KR101993009B1 (ko) | 노화의 효과에 대항하기 위한 경구 제제 | |
| Topal | The inhibition profile of sesamol against α-glycosidase and acetylcholinesterase enzymes | |
| CN118319935A (zh) | 一种还原型β-烟酰胺单核苷酸的药物用途 | |
| Ermer et al. | An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults | |
| Ren et al. | Escitalopram ameliorates Tau hyperphosphorylation and spatial memory deficits induced by protein kinase A activation in sprague dawley rats | |
| Yu et al. | The Effects of Radix Astragali Water Abstract on Energy Metabolism in Rat Yang‐Deficiency Cold Syndrome Model through PPAR Signaling Pathway | |
| Stamm et al. | Doxorubicin induces wide-spread transcriptional changes in the myocardium of hearts distinguishing between mice with preserved and impaired cardiac function | |
| Hamidovic et al. | Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers | |
| Hsieh et al. | Knocking down the transcript of protein kinase C-lambda modulates hypothalamic glutathione peroxidase, melanocortin receptor and neuropeptide Y gene expression in amphetamine-treated rats | |
| Sasaki et al. | A severely brain-damaged case of 3-hydroxyisobutyric aciduria | |
| Leslie et al. | Pompe Disease Synonyms: Acid Alpha-Glucosidase Deficiency, Acid Maltase Deficiency, GAA Deficiency, Glycogen Storage Disease Type II (GSD II), Glycogenosis Type II | |
| HK1168993B (en) | Genotype specific methods for treating human subjects using 4-methylpyrazole | |
| HK1168993A (en) | Genotype specific methods for treating human subjects using 4-methylpyrazole | |
| Mochizuki et al. | Prolonged central sensory conduction time in alcoholics with hypoactive aldehyde dehydrogenase-2 | |
| Lee et al. | Protective effect of maltol on pathological response of cardiomyocyte in dystrophic mice | |
| EP1888173A2 (en) | Novel use of (-)-epigallocatechin gallate | |
| Bose et al. | Investigating Developmental Toxicity of Phenylalanine and Phenylpyruvate: Insights from the Danio rerio Embryo Model | |
| Maron et al. | Tryptophan research in panic disorder | |
| Wei et al. | Curcumin Loaded with Ferric Oxide Nanoparticles Reduces Hypoxic Injury in Myocardial Infarction by Regulating miR-208 and Activating SIRT1 Signaling Pathway | |
| Burdo | One-carbon metabolism nutrients and DNA methylation in individuals with Anorexia Nervosa | |
| Caselli et al. | Age-Related Memory Decline and the APOE ω4 Effect | |
| Tyndale et al. | This study was supported by flagrant from International Research Supports, the Research Fund from Hirosaki University School of Medicine and flagrant from the |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170714 |